Clinical Trials Logo

Pulmonary Metastasis clinical trials

View clinical trials related to Pulmonary Metastasis.

Filter by:

NCT ID: NCT06235125 Not yet recruiting - Osteosarcoma Clinical Trials

Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

Cytalux
Start date: January 20, 2024
Phase: Phase 1
Study type: Interventional

Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.

NCT ID: NCT05676788 Not yet recruiting - Lung Neoplasm Clinical Trials

HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections

HYPER-Seg
Start date: April 2023
Phase: N/A
Study type: Interventional

The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.

NCT ID: NCT05518526 Recruiting - Soft Tissue Sarcoma Clinical Trials

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

ANNA-SARC
Start date: August 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-centre, open-label, single-arm, 3+3 Phase 1b/ and Phase II. Phase 1b is aimed to determine the maximum-tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) based on safety reporting. The RP2D is a multifactorial endpoint that considers toxicity as well as additional determinants (e.g. efficacy, pharmacodynamics) to define the optimal Phase 2 dose. Phase 2 will explore the efficacy of L-Annamycin at RP2D for treating soft tissue sarcomas (STS) subjects with lung metastases, for which chemotherapy is considered appropriate.

NCT ID: NCT05359393 Not yet recruiting - Liver Metastasis Clinical Trials

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

Miracle-1
Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

Although patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis. Based on previous studies, there is no confirmation of whether these patients could benefit from preoperative immunotherapy combined with conventional chemoradiotherapy. This study proposes a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis, to assess its impact on tumor retreat, decline of postoperative metastasis and recurrence, and the disease-free survival and overall survival of patients. Besides, this study will provide high-level medical evidence for future clinical treatment of patients with advanced rectal cancer.

NCT ID: NCT04887298 Active, not recruiting - Sarcoma,Soft Tissue Clinical Trials

Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

Start date: June 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.

NCT ID: NCT04854018 Completed - Rhabdomyosarcoma Clinical Trials

Indo-cyanine Green (ICG) in Paediatric Oncology MIS

Start date: April 30, 2021
Phase: Phase 4
Study type: Interventional

Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent during surgery. It has been used increasingly in the field of adult oncology surgery and has been shown to increase the efficacy of this surgery. The aim of this study is to evaluate the use of NIRF and ICG during specific minimally invasive surgery (MIS) procedures within paediatric oncology surgery. Their use will complement existing surgical techniques rather than replace them. Given the published advantages in adults this study aims to provide evidence of feasibility in the paediatric patients with cancer.

NCT ID: NCT04619472 Completed - Lung Neoplasms Clinical Trials

Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors

BRONC-RF?
Start date: January 7, 2021
Phase: N/A
Study type: Interventional

It is a multicenter, single group target value clinical trial to evaluate the safety and effectiveness of radiofrequency ablation for peripheral lung tumors under the conjunction of the pulmonary radiofrequency ablation system with the disposable pulmonary radiofrequency ablation catheter developed by Hangzhou Broncus Medical Co., Ltd.

NCT ID: NCT04066699 Completed - Clinical trials for Pulmonary Nodule, Solitary

Percutaneous Localization: Open-label Registry of Thoracic Surgery

PLOTS
Start date: October 10, 2019
Phase:
Study type: Observational [Patient Registry]

The objectives of this study are to evaluate intraoperative percutaneous lung lesion marking assisted by electromagnetic guided percutaneous navigation and related tools.

NCT ID: NCT03960021 Completed - Colo-rectal Cancer Clinical Trials

Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin

ARFIM
Start date: March 4, 2019
Phase: N/A
Study type: Interventional

Local percutaneous thermal ablation is frequently proposed in the management of metastatic diseases. Radiofrequency ablation (RFA) has demonstrated good results when the metastatic disease is limited and slowly evolving. The destruction of solid metastasis by RF leads to inflammatory and immunological mechanisms that remain poorly understood. These pathological events may influence the overall and anti-tumor host immune responses. The purpose of the study is to identify and quantify some immune mechanisms triggered by RFA of pulmonary metastases from colorectal cancer origin.

NCT ID: NCT03567538 Active, not recruiting - Lung Cancer Clinical Trials

National Register Studies in Thoracic Surgery

Start date: January 1, 2018
Phase:
Study type: Observational

The overall project aim is to study risk and outcomes following thoracic surgery by cross-linking high-quality national Swedish health-data registers for population-based investigations of individual level clinically relevant patient data.